|
|
The Application Value of Dynamic Electrocardiogram MTWA in Predicting MACE in Patients with Chronic Heart Failure |
HE Ya, LIU Fenxia |
Department of Cardiology,Baoji Hospital Affiliated to Xi'an Medical University,Baoji Shaanxi 721006 |
|
|
Abstract 【Objective】To explore the clinical value of microvolt T wave alternation(MTWA) in predicting major adverse cardiovascular events(MACE) in patients with chronic heart failure.【Methods】A total of 100 patients with CHF admitted to Baoji Hospital affiliated to Xi'an Medical College from December 2019 to December 2021 were selected and divided into MACE group(n=28) and non-MACE group(n=72) according to whether they had MACE. All patients underwent ambulatory electrocardiogram examination,and the risk factors for MACE in patients with CHF were analyzed using univariate and multivariate logistic regression analysis. The receiver operating characteristic(ROC) curve was used to evaluate the value of MTWA in predicting MACE in patients with chronic heart failure. 【Results】The age ≥65 years old,BMI ≥25 kg/m2,history of arrhythmia,smoking history,NYHA classification Ⅳ,history of hypertension,overwork history,and the proportion of V1 lead maximum MTWA(MTWAmax),maximum heart rate(MTWApeakhr),and average MTWA(MTWAoverall) in the MACE group were higher than those in the non-MACE group(P<0.05). ROC curve analysis showed that MTWAmax,MTWApeakhr,and MTWAoverall had higher values for predicting MACE in patients with CHF,with areas under the curve of 0.903,0.686,and 0.825,respectively(P<0.05). Logistic regression analysis showed that age ≥65 years old,history of arrhythmia,smoking history,NYHA classification Ⅳ,history of hypertension,overwork history,MTWAmax≥24.706,MTWApeakhr≥1.586,and MTWAoverall≥1.489 were all risk factors for MACE in patients with CHF(P<0.05). 【Conclusion】The application value of ambulatory electrocardiogram MTWA in predicting MACE in patients with chronic heart failure is high,and it is worthy of clinical reference.
|
Received: 10 August 2022
|
|
|
|
|
[1] COMÍN-COLET J,MANITO N,SEGOVIA-CUBERO J,et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure:The lion-heart multicentre randomised trial[J].Eur J Heart Fail,2018,20(7):1128-1136. [2] KOUZU H,KATANO S,YANO T,et al. Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure[J].ESC Heart Fail,2021,8(6):5045-5056. [3] ISHIKAWA H,IZUMIYA Y,SHIBATA A,et al. Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure[J].Heart Vessels,2020,35(5):681-688. [4] 边圆,王甲莉,程凯,等. 2016年欧洲心脏病学会急性心力衰竭指南解读[J].中华急诊医学杂志,2016,25(7):849-853. [5] LEE S,OH J,KIM H,et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J].ESC Heart Fail,2020,7(3):1125-1129. [6] 姜利明,朱永武. 基于动态心电图特征的慢性心力衰竭病人预后预测模型分析[J].中西医结合心脑血管病杂志,2022,20(2):281-284. [7] 李东程,唐园园,王垚,等. 微伏级T波电交替对心脏再同步治疗患者远期快速性室性心律失常发生的预测价值[J].中华心律失常学杂志,2021,25(3):244-248. [8] 孙喜文,陈海坚,吴小敏,等. 微伏级T波电交替和窦性心律震荡在冠心病诊断中的临床应用[J].海南医学,2016,27(11):1759-1761. [9] 冯吕晓,李树仁,李文静,等. 急性非ST段抬高型心肌梗死患者远期不良心血管事件危险因素筛选及预测评分系统构建[J].中国全科医学,2021,24(35):4457-4462. [10] 王新宏,朱参战,万招飞,等. 急性心肌梗死后射血分数保留型心力衰竭患者远期预后影响因素分析[J].中国心血管病研究,2019,17(8):715-718. [11] 任芳芳. 慢性心力衰竭患者心脏再同步治疗(CRT)术后出现抑郁焦虑障碍的影响因素及对预后的影响[J].国际精神病学杂志,2019,46(6):1089-1091. [12] 王焕霞,孙汝平,秦巧云,等. 心率减速力危险评价体系对心力衰竭患者预后的预测价值[J].中国全科医学,2019,22(9):1027-1032. [13] 王宇星,李闯,高元丰,等. 急性ST段抬高型心肌梗死后新发心房颤动与长期心血管不良事件的关系[J].医学研究生学报,2020,33(7):741-747. |
|
|
|